Sarcomatrix Therapeutics is a biopharmaceutical company developing oral small‑molecule treatments for Duchenne muscular dystrophy and related neuromuscular disorders. Its lead oral small‑molecule program is being advanced toward IND‑enabling studies with the goal of initiating first‑in‑human clinical trials. The company announced a $300,000 investment from Battle Born Venture to accelerate completion of IND‑enabling studies, manufacturing and CMC activities, and preparation of regulatory filings. Sarcomatrix aims to transition its lead program into the clinic and deliver effective, scalable therapies that are broadly accessible to patients and families worldwide. The company is seeking additional investors to complete a $5 million Seed round and may unlock up to $700,000 in matching funds from NBBGEI. The announcement was issued from Reno, Nevada, and described Sarcomatrix as a UNR spinout.

Total raised

$0M

Funding rounds

1

Latest round

Equity

Latest activity

Aug 2025